C-7H02Samsara Therapeutics
autophagy activation, phenotypic screening, iPSCs
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-7H02
C-7H02C-7H02autophagy activation, phenotypic screening, iPSCs
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Samsara Therapeutics autophagy activation, phenotypic screening, iPSCs
Samsara Therapeutics is pursuing therapeutics for neurodegenerative diseases through autophagy activation. Its portfolio includes programs for ALS, Parkinson's Disease, and Charcot-Marie-Tooth Disease, supported by a phenotypic screening platform in patient-derived iPSCs. The company was founded in 2019 and operates from Boston and Oxford.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Samsara Therapeutics — Far from goals · Bottom quartile. Derived deterministically from 5 extracted project(s). Most-advanced status: exploratory. Band: far. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic